Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
暂无分享,去创建一个
Renuka Pillutla | Boris Gorovits | Eric Wakshull | B. Gorovits | R. Pillutla | M. S. Manning | Yuanxin Xu | Yuanxin Xu | Jaya Goyal | Marta Starcevic Manning | E. Wakshull | J. Goyal
[1] Marian Kelley,et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.
[2] A. Janssens. Romiplostim for the treatment of primary immune thrombocytopenia , 2012, Expert review of hematology.
[3] S. Zeuzem,et al. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy , 2001, Expert opinion on investigational drugs.
[4] Daniela Verthelyi,et al. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.
[5] Viswanath Devanarayan,et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.
[6] P. Ruf,et al. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels , 2008, International journal of cancer.
[7] Gopi Shankar,et al. Scientific and regulatory considerations on the immunogenicity of biologics. , 2006, Trends in biotechnology.
[8] H. Okudaira,et al. Reaginic antibody formation in the mouse. II. Enhancement and suppression of anti-hapten antibody formation by priming with carrier. , 1973 .
[9] R Seitz,et al. Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[10] J. M. Harris,et al. Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.
[11] M. Hershfield,et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.
[12] Robin Marsden,et al. Summary of Confirmation Cut Point Discussions , 2011, The AAPS Journal.
[13] M. Raff,et al. The carrier effect in the secondary response to hapten‐protein conjugates. II. Cellular cooperation , 1971, European journal of immunology.
[14] D. Dimmock,et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease , 2012, Genetics in Medicine.
[15] Emma D. Deeks. Certolizumab Pegol , 2013, Drugs.
[16] H. Hartung,et al. Atacicept: targeting B cells in multiple sclerosis , 2010, Therapeutic advances in neurological disorders.
[17] L L Miller,et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. , 1999, Blood.
[18] D. Mason,et al. Deaggregated homologous immunoglobulin‐peptide conjugates induce peptide‐specific T cell nonresponsiveness in vivo , 1998, European journal of immunology.
[19] D. Stanworth,et al. Factors influencing the immunogenicity of the haptenic drug chlorhexidine in mice. II. The role of the carrier and adjuvants in the induction of IgE and IgG anti-hapten responses. , 1986, Immunology.
[20] E. Vitetta,et al. The use of haptenated immunoglobulins to induce B cell tolerance in vitro. The roles of hapten density and the Fc portion of the immunoglobulin carrier. , 1983, Journal of immunology.
[21] Rosenberg As. Immunogenicity of biological therapeutics: a hierarchy of concerns. , 2003, Developments in biologicals.
[22] P. V. Schouwenburg,et al. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.
[23] Guy Georges,et al. The intriguing options of multispecific antibody formats for treatment of cancer. , 2013, Cancer genomics & proteomics.
[24] Viswanath Devanarayan,et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.
[25] Dan Lu,et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer , 2012, Cancer Chemotherapy and Pharmacology.
[26] Y. Inada,et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. , 1995, Trends in biotechnology.
[27] T. Boone,et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.
[28] J. Bluestone,et al. Pathologic Role and Temporal Appearance of Newly Emerging Autoepitopes in Relapsing Experimental Autoimmune Encephalomyelitis1 , 2000, The Journal of Immunology.
[29] D. Scott,et al. Epitope-specific tolerance induction with an engineered immunoglobulin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Seimetz,et al. Catumaxomab: clinical development and future directions. , 2010, mAbs.
[31] A. Compston,et al. A Novel Strategy To Reduce the Immunogenicity of Biological Therapies , 2010, The Journal of Immunology.
[32] T. Ishida,et al. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[33] P. Lampertico,et al. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history , 2013, Expert review of anti-infective therapy.
[34] L. Lundquist. Abatacept: a novel treatment for rheumatoid arthritis , 2007, Expert opinion on pharmacotherapy.
[35] Pascal Richette,et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.
[36] I. Nestorov,et al. A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology , 2012, Journal of clinical pharmacology.
[37] V. Tuohy,et al. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease , 1996, The Journal of experimental medicine.
[38] Daniel Baltrukonis,et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. , 2011, Journal of pharmaceutical and biomedical analysis.
[39] R. Kinkel,et al. Diversity and plasticity of self recognition during the development of multiple sclerosis. , 1997, The Journal of clinical investigation.
[40] P. Senter,et al. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.
[41] L. Garrison,et al. Etanercept: therapeutic use in patients with rheumatoid arthritis , 1999, Annals of the rheumatic diseases.
[42] P. Fournier,et al. Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer , 2012, BioDrugs.
[43] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.
[44] C. Won,et al. PEG-modified biopharmaceuticals , 2009 .
[45] A. Ohtsu,et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors , 2012, Cancer Chemotherapy and Pharmacology.
[46] Huub Schellekens,et al. The Immunogenicity of Polyethylene Glycol: Facts and Fiction , 2013, Pharmaceutical Research.
[47] A. Wahl,et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] Arunan Kaliyaperumal,et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. , 2013, Bioanalysis.
[49] S. Mouritsen,et al. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. , 1997, Molecular immunology.
[50] J. W. Lindsey. Use of reinduced experimental autoimmune encephalomyelitis to evaluate the importance of epitope spread. , 1998, International immunology.
[51] A. Thakur,et al. Activated T cells from umbilical cord blood armed with anti‐CD3 × anti‐CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants , 2012, Transfusion.
[52] Ray Yin,et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. , 2011, Journal of pharmacological and toxicological methods.
[53] Gopi Shankar,et al. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.